| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 04/22/2004 | US20040077828 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 04/22/2004 | US20040077704 Fused cyclopenta-, cyclohexa-, or cyclohepta(g)indole derivatives as human non-pancreatic secretory phospholipase inhibitors; antiinflammatory agents |
| 04/22/2004 | US20040077701 Pyrazole derivates for treatment of osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer*s disease |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077693 Integrin receptor inhibitors |
| 04/22/2004 | US20040077684 Piperidinyl compounds that selectively bind integrins |
| 04/22/2004 | US20040077680 Ureaacylated indazole, benzisoxazole, or benzisothiazole derivative with monocyte chemoattractant protein inhibitors; antiinflammatory agents; autoimmune diseases; arthritis, asthma, atherosclerosis, diabetes |
| 04/22/2004 | US20040077667 Quinazolinone derivatives |
| 04/22/2004 | US20040077663 Thienopyrimidine-based inhibitors of the src family |
| 04/22/2004 | US20040077658 Respiratory system, nervous system, brain, gastrointestinal and psychological disorders; chronic obstructive pulmonary disease; antiasthmatics, analgesics |
| 04/22/2004 | US20040077648 Antiproliferative agents for smooth muscle cells; antiinflammatory agents for endothelial cells; restenosis, atherosclerosis |
| 04/22/2004 | US20040077645 Xanthine derivatives,production and use thereof as medicament |
| 04/22/2004 | US20040077632 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/22/2004 | US20040077629 Such as 4-methyl-2-hydroxy-2-(4-hydroxy-4-methylpentyl)-butanediocate ester cephalotaxine derivative |
| 04/22/2004 | US20040077619 Calcium receptor modulating agents |
| 04/22/2004 | US20040077614 High, sustained blood concentration levels even during pregnacy without hepatic side effects; 3,17-dipropionate or dihexanoate; multiple sclerosis |
| 04/22/2004 | US20040077612 Acting as prodrugs; higher concentration delivery of active material to target cell in hybrid form; decreasing side effects |
| 04/22/2004 | US20040077592 Cross-linked polysaccharide drug carrier |
| 04/22/2004 | US20040077525 Novel treatment |
| 04/22/2004 | US20040077079 Methods, kits and production plant for use in the production of cell colony forming units from a mammalian tissue explant and to the use of cells from such cell colony forming units in treatment of mammals suffering from tissue disorders |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040076680 Obtained by means of physico-chemical crosslinking of the derivatives of high-molecular-weight hyaluronic acid or salts thereof; antiarthritic agents |
| 04/22/2004 | US20040076626 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | CA2782847A1 Methods of administering fgf18 |
| 04/22/2004 | CA2501833A1 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
| 04/22/2004 | CA2500385A1 Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor |
| 04/22/2004 | CA2500317A1 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409715A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409672A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 04/21/2004 | EP1409658A2 Aggrecanase molecules |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409643A1 Probiotic lactobacillus casei strains |
| 04/21/2004 | EP1409540A2 Melanocortin receptor ligands |
| 04/21/2004 | EP1409539A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409491A2 Thienopyrimidine-based inhibitors of the src family |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409487A1 Pteridinones as kinase inhibitors |
| 04/21/2004 | EP1409485A1 Novel immunomodulating compounds |
| 04/21/2004 | EP1409483A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 04/21/2004 | EP1409481A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 04/21/2004 | EP1409463A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/21/2004 | EP1409455A1 Prostaglandin analogues-as ep4 receptor agonists |
| 04/21/2004 | EP1409453A1 Novel diamines having a casr modulating activity |
| 04/21/2004 | EP1409404A1 Calcium phosphate nanoclusters and their applications |
| 04/21/2004 | EP1409077A2 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 04/21/2004 | EP1409016A2 Antibodies to opgl |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409007A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1408999A1 Compositions addressing inflammation and/or degenerative disorders |
| 04/21/2004 | EP1408990A2 Use of hyaluronic acid uronides for the treatment of inflammatory processes |
| 04/21/2004 | EP1408988A1 Compositions of orally administered nutritional supplements to repair articular cartilage |
| 04/21/2004 | EP1408987A2 Tetracycline compounds having target therapeutic activities |
| 04/21/2004 | EP1408985A1 Novel pyridopyrimidones and uses thereof |
| 04/21/2004 | EP1408984A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 04/21/2004 | EP1408962A1 Substituted isoindoles and the use thereof |
| 04/21/2004 | EP1408961A1 2 pyrrolidone derivatives as prostanoid agonists |
| 04/21/2004 | EP1408951A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 04/21/2004 | EP1408950A2 Methods of treating cytokine mediated diseases |
| 04/21/2004 | EP1408947A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 04/21/2004 | EP1408943A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 04/21/2004 | EP1408934A2 Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate |
| 04/21/2004 | EP1296946B1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 04/21/2004 | EP1272481B1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 04/21/2004 | EP1154987B1 Phenylalaninol derivatives |
| 04/21/2004 | EP1105370B1 Novel aryl sulphonamides and analogues |
| 04/21/2004 | EP0856007B1 Cyclopeptide derivatives |
| 04/21/2004 | CN1491230A Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy |
| 04/21/2004 | CN1491225A Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as active ingredient |
| 04/21/2004 | CN1491222A Piperidinee derivatives as neurokinin/antagonists |
| 04/21/2004 | CN1491208A Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical |
| 04/21/2004 | CN1491207A Acylated indanyl amines and their use as pharmaceuticals |
| 04/21/2004 | CN1491197A Tropolone derivative |
| 04/21/2004 | CN1491115A Use of botulinum toxin for treatment of articular pathologies |
| 04/21/2004 | CN1490335A Method and application of expressions of sTNFR immuno desmolin fusion protein and polypeptide |
| 04/21/2004 | CN1490044A Medicine for treating osteoproliferation |
| 04/21/2004 | CN1490034A Medicine composition for treating pain in waist and lower limbs and hyperosteogeny |
| 04/21/2004 | CN1490017A Medicines against rheunatoid and rheumatic diseases |
| 04/21/2004 | CN1489996A Diclofenac sodium pastes and preparation thereof |
| 04/21/2004 | CN1146545C Benzoylpyridazines |
| 04/21/2004 | CN1146542C Benzamide derivatives and their use as cytokine inhibitors |
| 04/21/2004 | CN1146541C Beta-alanine derivatives |
| 04/21/2004 | CN1146438C External use medicine bag for stagnation-syndrome |
| 04/20/2004 | US6723747 Estrogen receptor modulators useful in treating or inhibiting conditions, disorders, or disease states at least partially mediated by estrogen deficiency or excess, or which may be treated or inhibited through use of estrogenic agent |
| 04/20/2004 | US6723744 Indole carboxylic acids as thyroid receptor ligands |
| 04/20/2004 | US6723736 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (tnf-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (cox-2) |
| 04/20/2004 | US6723730 Capsaicin receptor ligands |
| 04/20/2004 | US6723727 Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| 04/20/2004 | US6723696 Drug screening for agents to treat hypercalcemia and osteoporosis |
| 04/20/2004 | US6723525 Methods and compositions for screening modulators of lipid kinases |
| 04/20/2004 | US6723350 Powder of one or more antimicrobial metals formed with atomic disorder; coating becomes antimicrobial and anti-inflammatory when wet. |